If you’ve spent months or years trying antidepressants without real relief, you’ve probably reached the point where the question is no longer if you should try something different. The question is what to try next. Two treatments come up more than any others at this stage: TMS and ketamine. Both are legitimate, evidence-based options, and both can produce real results in people who haven’t responded to traditional medications.
But they aren’t interchangeable, and choosing between them isn’t a matter of picking the newer one or the stronger one. They work through entirely different biological mechanisms, fit into daily life in different ways, and suit different clinical situations. The right choice for one person may be wrong for another, even with the same diagnosis. Rather than rank one above the other, this guide walks through the factors that actually influence which treatment makes more sense as a starting point: how quickly you need relief, what your schedule allows, what your medical history includes, and what your symptoms look like right now.
Start with what these treatments actually do, because the difference runs deeper than most people expect. They target the brain through completely separate pathways, which is precisely why one may succeed where the other has not.
TMS, or Transcranial Magnetic Stimulation, works from the outside in. A device placed near the scalp delivers focused magnetic pulses to specific brain regions, most commonly the left dorsolateral prefrontal cortex, an area closely tied to mood regulation that tends to show reduced activity in depression. The pulses stimulate the underlying neurons, encouraging them to fire more consistently over time. The process is gradual and cumulative: the brain is retrained rather than rapidly altered. No drugs, no sedation, no systemic effects on the rest of the body.
Ketamine and its FDA-approved nasal spray form, SPRAVATO (esketamine), work through a different mechanism entirely. Ketamine acts on NMDA receptors and rapidly modulates glutamate signaling. Glutamate is the brain’s primary excitatory neurotransmitter, often dysregulated in depression, and ketamine’s effect on this system can produce antidepressant changes within hours to days, a fundamentally different speed of action than anything in traditional psychiatry. SPRAVATO received FDA approval in 2019 for treatment-resistant depression and for major depressive disorder with acute suicidal ideation or behavior. IV ketamine is used off-label for depression but is widely administered in clinical settings with strong supporting evidence.
Here’s why the distinction matters in practice. If multiple antidepressants haven’t worked, it may be because the serotonin and norepinephrine pathways those medications target aren’t the primary driver of your depression. TMS approaches the problem through neurological stimulation. Ketamine approaches it through a completely different receptor system. Neither is a stronger version of what you’ve already tried; they’re different tools, and for many people that’s exactly why one works when nothing else has. You can learn more about how we approach each on our Deep TMS page and our ketamine therapy page.
For some people, how quickly a treatment works is the deciding factor.
Ketamine can produce noticeable antidepressant effects within hours to days of the first treatment. For someone in acute distress, barely functioning, or struggling with thoughts of suicide, that speed can be essential rather than merely convenient. SPRAVATO’s FDA approval for major depressive disorder with acute suicidal ideation reflects how seriously the clinical community takes ketamine’s rapid onset in high-risk situations. When someone is at their lowest point and needs stabilization now, waiting four to six weeks to see if a treatment is working isn’t always realistic or safe.
TMS runs on a different timeline. Most patients begin noticing improvement between the third and fifth week of treatment, with the full benefit typically emerging by the end of a six-to-seven-week course. That reflects the nature of what TMS does: gradually reshaping neural activity through consistent stimulation. For people who are psychiatrically stable but stuck in a depression that hasn’t lifted despite multiple medication trials, this timeline works fine. They aren’t in crisis. What they need is a sustained, structured approach that produces durable improvement, and TMS is built for that.
A useful way to think about it: where are you right now? Can you commit to a multi-week schedule, attend sessions five days a week, and wait for gradual improvement? Or is the weight of your depression heavy enough that you need something to shift quickly just to reach a point where you can function and engage with longer-term care? Neither answer is better or worse, but they point in different directions. The first points toward TMS. The second makes ketamine or SPRAVATO the stronger candidate as a first step, potentially followed by TMS once you’re more stable. This is exactly the assessment we work through with every patient before making a recommendation.
A treatment that’s theoretically ideal but practically impossible to maintain isn’t a good treatment plan, so the logistics deserve real attention.
TMS asks for a big time commitment upfront: sessions five days per week for six to seven weeks, each lasting 20 to 40 minutes depending on the protocol. The upside is that TMS requires no sedation and no recovery time. You can drive yourself, return to work immediately afterward, and keep your normal routine. For people working full time or handling caregiving duties, the frequency can feel demanding, but the sessions themselves barely disrupt the rest of the day.
Ketamine and SPRAVATO are structured differently. There are fewer sessions, typically an induction phase over a few weeks followed by maintenance treatments as needed, but each session carries requirements. SPRAVATO is administered in a certified healthcare setting with a mandatory two-hour monitoring period after each dose, and IV infusions also require post-session monitoring. Because both forms can cause dissociative effects, you can’t drive yourself home and need transportation arranged for every appointment. For someone without a reliable driver or with an inflexible schedule, that’s a real barrier.
So think through your week. Do you have a consistent two-hour window a few times per week, plus someone who can reliably drive you? Or is it easier to fit in a short daily session you can drive to yourself? Do work or childcare obligations make a post-session monitoring period hard to accommodate? These aren’t reasons to avoid either treatment. They’re factors to name openly so the plan you commit to is one you can actually follow through on.
Your medical and psychiatric history shapes which treatment is the safer starting point, and in some cases it rules one out entirely.
TMS has a short list of firm contraindications. Certain metallic implants near the head, such as cochlear implants, aneurysm clips, or metal plates in the skull, generally rule it out because of the magnetic field. A history of seizures or epilepsy requires careful evaluation and may preclude TMS in many cases. Outside those situations, TMS is a very safe procedure with a well-established tolerability profile.
For patients with a history of substance use concerns, TMS is often the more straightforward choice, since ketamine carries known abuse potential even in controlled clinical use. TMS also avoids dissociative effects entirely, which matters for patients with certain trauma histories or conditions that make altered perception hard to tolerate.
Ketamine has its own caution list. Uncontrolled high blood pressure is a concern because ketamine temporarily raises blood pressure during treatment. A personal or family history of psychosis or schizophrenia is generally a contraindication, since ketamine can worsen psychotic symptoms. Certain substance use histories warrant careful review before it’s prescribed.
On the other side, ketamine is often the right call when speed of response is medically necessary. Active suicidal ideation is the clearest example: when someone is in acute danger, rapid relief may be the clinically responsible choice. Severe functional impairment, where depression has made it hard to work, maintain relationships, or care for yourself, can also favor ketamine as a first step toward enough stability to engage in longer-term treatment. You don’t need to sort these factors out on your own; a thorough psychiatric evaluation surfaces all of them.
Neither TMS nor ketamine works for everyone. That’s not a failure of the treatments, and it’s not a failure of the patient. Treatment-resistant depression has by definition already proven difficult, and sometimes the first advanced treatment doesn’t produce the hoped-for result.
The two aren’t mutually exclusive, though. Some patients do best with a sequential approach, using ketamine first for rapid stabilization, then TMS to build on that improvement and create more durable change. Others get partial improvement from one treatment and add the other to fill in what’s missing. We evaluate combinations case by case, because no single protocol fits every patient.
Neurofeedback can also work alongside either treatment. Using EEG-based brain monitoring, it helps patients learn to regulate their own brain activity over time, reinforcing and extending gains from TMS or ketamine, particularly around emotional regulation and cognitive functioning. Medication management is another layer that may be adjusted in parallel.
If a full course of TMS doesn’t produce a response, or a ketamine induction series falls short, that isn’t the end of the road. It’s information. It tells us how your brain is responding and shapes what we recommend next. Our approach is an ongoing clinical relationship, not a single transaction, and we stay engaged through the full arc of treatment. You can see our full range of services at our homepage.
People considering advanced treatments often feel pressure to arrive knowing what they want. They’ve done the research, read about both options, and feel they should walk in with an answer. That’s not how this works, and it’s not what we expect.
Our process starts with a thorough psychiatric evaluation: a real clinical conversation covering your full treatment history, every medication you’ve tried and how you responded, your current symptoms, your daily functioning, your medical history, and your goals. From there we identify which treatment is the more appropriate starting point for you specifically. Sometimes the answer is clear. Sometimes there are real tradeoffs to weigh together, and we talk through them openly, explain our reasoning, and answer your questions.
The decision is collaborative. You aren’t handed a treatment plan and told to comply. Your preferences, schedule, concerns, and priorities all shape the recommendation. We’ve seen both treatments change lives, and we’ve seen patients need more than one approach before finding what works. Either way, we’re with you through the process.
Both TMS and ketamine are real options, and both are treatments we offer with full clinical support. Which one is right for you doesn’t have a universal answer, but it has an answer for your specific situation, and it comes from a proper evaluation rather than reading alone.
At Delray Brain Science, we take the time to understand where you are before we tell you where to go next. Schedule a consultation with our team; you don’t need to have it figured out before you reach out. That’s what we’re here for.
